# ScoreItem: Transaminase oxalacética (AST)

**ID:** `019bf31d-2ef0-7302-bf07-5ec62b78567b`
**FullName:** Transaminase oxalacética (AST) (Exames - Laboratoriais)
**Unit:** U/L

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 2 artigos
- Avg Similarity: 0.624

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7302-bf07-5ec62b78567b`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7302-bf07-5ec62b78567b",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto clínico: 1-9 pts
- Alto impacto clínico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Critérios: gravidade/mortalidade (40%), prevalência (30%), intervencionabilidade (30%)

---

### Contexto Científico

**ScoreItem:** Transaminase oxalacética (AST) (Exames - Laboratoriais)
**Unidade:** U/L

**30 chunks de 2 artigos (avg similarity: 0.624)**

### Chunk 1/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.671

talmyocytes,anderythrocytes.TherelativeactivityofASTinvarioustissuesandcellsisasfollows:7800intheheart,7100intheliver,5000intheskeletalmuscle,4500inthekidney,2500inthebrain,1400inthepancreas,700inthespleen,500inthelung,and40inerythrocytes[1].Therefore,elevatedserumASTlevelscanbeobservedinawidespectrumofnon-hepaticdisorders,suchas
J.Clin.Med.2023,12,310.https://doi.org/10.3390/jcm12010310https://www.mdpi.com/journal/jcm

J.Clin.Med.2023,12,310
2of12
acutecoronarysyndrome,renalinfarction,cerebralinfarction,rhabdomyolysis,pulmonaryembolism,andhemolysis[2,3].Elevatedaminotransferaselevelsduetonon-hepaticcausesarefrequentlyencounteredinclinicalpractice.Skeletalmuscledamage(i.e.,rhabdomyolysis)isoneofthemostcommonnon-hepaticcausesofelevatedaminotransferaselevels.Themortalityrateofrhabdomyolysiswasreportedtobe3–9%innon-intensivecareunit(ICU)patientsand7–46%inICUpatients[4–10].Cardiacmuscledamage,suchasduetoacutemyocardialinfarctionandmyocarditis,isalsooneofthecommonnon-hepaticcausesofel

---

### Chunk 2/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.666

l variations, and reference 
values. Clin Chem 1975;21:1077-87.140. Ruhl CE, Everhart JE. Determinants of the 
association of overweight with elevated serum 
alanine aminotransferase activity in the United States. 
Gastroenterology 2003;124:71-9.141. Ioannou GN, Boyko EJ, Lee SP. The prevalence and 
predictors of elevated serum aminotransferase activity 
in the United States in 1999-2002. Am J Gastroenterol 
2006;101:76-82.142. Zamin JI, de Mattos AA, Perin C, Ramos GZ. [The 
importance of AST / ALT rate in nonalcoholic 
steatohepatitis diagnosis]. Arq Gastroenterol 2002;39:22-
6.143. Nanji AA, French SW, Freeman JB. Serum alanine 
aminotransferase to aspartate aminotransferase ratio 
and degree of fatty liver in morbidly obese patients. 
Enzyme 1986;36:266-9.144. Pratt DS, Kaplan MM. Evaluation of abnormal liver-
enzyme results in asymptomatic patients. N Engl J Med 
2000;342:1266-71.145. Josekutty J, Iqbal J, Iwawaki T, Kohno K, Hussain 
MM.

---

### Chunk 3/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** introduction | **Similarity:** 0.658

I=1.36–6.35),andpeakAST�3000U/L(OR=9.61,95%CI=3.54–26.08)wereassociatedwithincreased30-daymortality.OurstudyrevealedthreeetiologiesofmarkedlyelevatedASTunrelatedtoliverdiseaseandshowedthatetiologyandpeakASTlevelsigniﬁcantlyaffectedthesurvivalrate.Keywords:elevatedaspartateaminotransferase;etiology;acutemyocardialinfarction;rhabdomyolysis;hemolysis
1.IntroductionAlanineaminotransferase(ALT)andaspartateaminotransferase(AST)areoftenre-ferredtoasliverfunctiontests,butratherthanbeingtruemeasurementsofhepaticfunction,thereleaseofASTandALTfromhepatocytesintothebloodstreamrepresentshepatocel-lularinjury.ALTismorespeciﬁcforhepatocellularinjurybecauseofitsmuchhigherconcentrationinthelivertissuethaninothertissues.Incontrast,ASTiswidelydetectedinvariouscells,suchashepatocytes,cardiacandskeletalmyocytes,anderythrocytes.TherelativeactivityofASTinvarioustissuesandcellsisasfollows:7800intheheart,7100intheliver,5000intheskeletalmuscle,4500inthekidney,2500inthebrain,1400inthepancreas,700inthes

---

### Chunk 4/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.652

asreportedtobe3–9%innon-intensivecareunit(ICU)patientsand7–46%inICUpatients[4–10].Cardiacmuscledamage,suchasduetoacutemyocardialinfarctionandmyocarditis,isalsooneofthecommonnon-hepaticcausesofelevatedaminotransferases.InapreviousCanadianstudy,ASTelevationabovetheupperlimitofnormal(ULN)occurredin85.6%ofpatientswithST-elevationmyocardialinfarction(STEMI),withmarkedlyelevatedAST(>10timestheULN)occurringin3.3%[11].Inotherstudies,markedlyelevatedASTlevelsoccurredin3–5%ofpatientswithSTEMI[12,13].TheyalsoidentiﬁedthatelevatedASTwasassociatedwithincreasedmortalityinthesepatients.Inpatientswhounderwentcoronaryarterybypassgraftsurgery,anelevatedpostoperativeASTlevel(>300U/L)wasanindependentpredictorofmortality[14].Apartfrommuscledamage,elevatedASTlevelsfromhematologicdisordersarealsooccasionallyencounteredinclinicalpractice.SeveralcaseseriesofASTelevationsinmalignantandnon-malignanthematologicdisordershavebeenreported[15–18].Itiswell-knownthatmarkedelevationofaminotransferaselevelsis

---

### Chunk 5/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.648

o theoretically be due to a reduction in AST 
clearance,38 in practice an in vivo isolated elevation of AST is usually due to injury to non-liver cells, particularly cells that 
contain mitochondria, and therefore is especially indicative of 
rhabdomyolysis.RhabdomyolysisRelease of muscular AST (and to a much lesser extent 
muscular ALT) can occur with exercise leading to increased 
serum transaminases.39,40 More severe muscle damage or rhabdomyolysis will cause larger elevations of serum AST 
(and to a lesser extent ALT), however creatine kinase (CK) 
is the serum enzyme of choice in estimating the degree of 
rhabdomyolysis, because the levels of CK in muscle are an 
order of magnitude higher than the transaminases.41Because both CK (t½=12 h) and AST (t½=18 h) decline rapidly, and ALT (t½=36 h) declines relatively slowly,42 studies have shown that the AST/ALT ratio, which is high in acute skeletal 
muscle injury, can fall towards 1:1 after a few days due to the faster decline in AS

---

### Chunk 6/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.642

etotheirhighmortality.Inthisstudy,among5644patientswithAST>400U/L,only7.6%werefoundtobeassociatedwithnon-hepaticcauses.ThissuggeststhatmarkedlyelevatedASTlevelsunrelatedtoliverdiseasemaynotbeencounteredfrequentlyinclinicalpractice.Therefore,wepresentasimpliﬁedschematicapproachforpatientswithmarkedlyelevatedASTlevelsunrelatedtoliverdisease,involving(1)determinationoftheetiology(skeletalmuscledamage,cardiacmuscledamage,orhematologicdisorder)and(2)measurementofthepeakASTlevelduringfollow-uptesting(<1000U/L,<3000U/L,or�3000U/L)(Figure4).OnelimitationofthisstudyisthattheetiologyofmarkedlyelevatedASTlevelscouldnotbedeterminedprospectively.Anotherlimitationisthatadditionalliverdamage,includingischemicinjury,multipleorganfailure,anddrug-inducedliverinjury,mayhavecontributedtothemagnitudeofASTlevelsduringfollow-uptesting,althoughtherewasnoevidenceofliverdiseaseatenrollmentinallpatients.Inaddition,weonlyfocusedon30-daymortalityinpatientswithmarkedlyelevatedAST.Therefore,furtherprospectivestu

---

### Chunk 7/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.638

uation of abnormal liver-
enzyme results in asymptomatic patients. N Engl J Med 
2000;342:1266-71.145. Josekutty J, Iqbal J, Iwawaki T, Kohno K, Hussain 
MM. Microsomal triglyceride transfer protein inhibition 
induces endoplasmic reticulum stress and increases �gene transcription via Ire1α/cJun to enhance plasma 
ALT/AST. J Biol Chem 2013;288:14372-83.146. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, 
Zein NN, McCullough AJ. Cytokeratin-18 fragment 
levels as noninvasive biomarkers for nonalcoholic 
steatohepatitis: a multicenter validation study. 
Hepatology 2009;50:1072-8.147. Kawamoto R, Kohara K, Kusunoki T, Tabara Y, 
Abe M, Miki T. Alanine aminotransferase/aspartate 
aminotransferase ratio is the best surrogate marker 
for insulin resistance in non-obese Japanese adults. 
Cardiovasc Diabetol 2012;11:117.148. Sookoian S, Pirola CJ. Alanine and aspartate 
aminotransferase and glutamine-cycling pathway: their 
roles in pathogenesis of metabolic syndrome.

---

### Chunk 8/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** methods | **Similarity:** 0.634

ct the cellular proportions where AST 
is over twice as prevalent than ALT.5 The Use of Enzyme Ratios
De Ritis described the AST/ALT ratio as being a useful 
indicator of the aetiology of hepatitis (e.g. acute viral 
hepatitis)1 and his work was confirmed and extended by Wroblewski.6 Over the following decades, subsequent studies using improved transaminase methods continued to confirm 
the original work.7-9Other enzyme ratios have also been suggested to have similar 
utility for identification of viral hepatitis such as the ratio of 
the sum of serum AST+ALT activities divided by the serum 
Figure 1. The role of ALT in the glucose-alanine cycle between muscle to liver.Table 1. Relative activity of transaminases in human tissues.*
AST ActivityALT ActivityAST/ALT RatioWeight (kg)AST TotalALT TotalLiver7,1002,8502.51.510,6504,275Kidney4,5001,2003.80.251,125300Heart7,800450170.32,340135Muscle5,0003001730150,0009,000Serum111.0333*Adapted from King J.

---

### Chunk 9/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.632

causeofmarkedlyelevatedASTlevelswasskeletalmuscledamage(54.2%),followedbycardiacmuscledamage(39.1%)andhematologicdisorders(6.7%).PatientswithmarkedlyelevatedASTlevelsunrelatedtoliverdiseasehada30-daymortalityrateof20%.ThemagnitudeofthepeakASTlevelsandetiologyofelevatedASTlevelswereindependentriskfactorsof30-daymortality.ASTactivityhasbeenwidelydetectedinvarioushumantissues.ItisgenerallythoughtthatincreasedlevelsofcirculatingASTmayreﬂectdirecttissuedamageandapoptosisrelatedtoliverinﬂammation,septicshock,acutemyocardialinfarction,andskeletalmuscleinjury[19].Infact,plasmamembraneblebscontainingcytosoliccomponentshavebeendemonstratedduringischemia-reperfusioninjuriesinthemyocardiumandliver[20].Skele-talmuscleisknowntocontainintracellularproteinssuchasmyoglobinandisozymessuchasCK,lactatedehydrogenase,AST,andALTwhichmaybereleasedintothecirculationfollowingmuscleinjury[21].ElevatedASTlevelsduetocardiacmuscledamagemaythusbeexplainedbythereleaseofASTfromthemyocardiumduetoincreasedstress,acu

---

### Chunk 10/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** abstract | **Similarity:** 0.632

Therehavebeennoreportsonmortalityinpatientswithmarkedlyelevatedaspartateaminotransferase(AST)levelsfromnon-hepaticcausestodate.ThisstudyaimedtodeterminetheetiologiesofmarkedlyelevatedASTlevels>400U/Lduetonon-hepaticcausesandtoinvestigatethefactorsassociatedwithmortalityinthesecases.Thisretrospectivestudyincluded430patientswithASTlevels>400U/LunrelatedtoliverdiseaseattwocentersbetweenJanuary2010andDecember2021.Patientswereclassiﬁedintothreegroupsaccordingtoetiology:skeletalmuscledamage,cardiacmuscledamage,andhematologicdisorder.Binarylogisticregressionanalysiswasperformedtoevaluatethefactorsassociatedwith30-daymortality.ThemostcommonetiologyformarkedlyelevatedASTlevelswasskeletalmuscledamage(54.2%),followedbycardiacmuscledamage(39.1%)andhematologicdisorder(6.7%).The30-daymortalityratesfortheskeletalmuscledamage,cardiacmuscledamage,andhematologicdisordergroupswere14.2%,19.5%,and65.5%,respectively.ThemagnitudeofthepeakASTlevelsigniﬁcantlycorrelatedwith30-daymortality,withratesof12.8%,26.7%,and50.0%forpeakASTlevels<1000U/L,<3000U/L,and�3000U/L,respectively.Inthemultivariateanalysis,cardiacmuscledamage(oddsratio[OR]=2.76,95%conﬁdenceinterval[CI]=1.31–5.80),hematologicdisorder(OR=9.47,95%CI=2.95–30.39),peakAST<3000U/L(OR=2.94,95%CI=1.36–6.35),andpeakAST�3000U/L(OR=9.61,95%CI=3.54–26.08)wereassociatedwithincreased30-daymortality.OurstudyrevealedthreeetiologiesofmarkedlyelevatedASTunrelatedtoliverdiseaseandshowedthatetiologyandpeakASTlevelsigniﬁcantlyaffectedthesurvivalrate.

---

### Chunk 11/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.630

ses are elevated with rhabdomyolysis in 
the absence of significant liver injury. J Med Toxicol 
2010;6:294-300.43. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. 
Serum alanine aminotransferase in skeletal muscle 
diseases. Hepatology 2005;41:380-2.44. Pettersson J, Hindorf U, Persson P, Bengtsson T, 
Malmqvist U, Werkström V, et al. Muscular exercise 
can cause highly pathological liver function tests in 
healthy men. Br J Clin Pharmacol 2008;65:253-9.45. Helfgott SM, Karlson E, Beckman E. Misinterpretation 
of serum transaminase elevation in “occult” myositis. 
Am J Med 1993;95:447-9.46. Price CP, Alberti KG. Biochemical assessment of 
liver function. In: Wright R, Alberti KGMM, Karran 
S, Millward-Sadler GH, editors. Liver and Biliary 
Disease -Pathophysiology, Diagnosis and Management. 
London: W.B. Saunders; 1979:381-416.47. Pertusi R, Dickerman RD, McConathy WJ.

---

### Chunk 12/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.628

t½=36 h) declines relatively slowly,42 studies have shown that the AST/ALT ratio, which is high in acute skeletal 
muscle injury, can fall towards 1:1 after a few days due to the faster decline in AST.43,44 In chronic muscle injury such as polymyositis, the ALT is much the same as the AST45 and this is consistent with the expected faster clearance of AST 
compared to ALT.46The persistence of elevated ALT following rhabdomyloysis 
may also result in the misdiagnosis of hepatitis, such as 
when hepatitis is attributed to the hepatic effects of anabolic 
steroids47 rather than the more obvious association of these substances with skeletal muscle dysfunction. Elevated serum 
ALT levels in the absence of other evidence of liver disease 
should lead to consideration of chronic or resolving muscle 
injury.48Acute Viral Hepatitis
While it is clearly recognised that serum levels of both serum 
ALT and AST are elevated several fold in ‘acute’ viral hepatitis 
(e.g.

---

### Chunk 13/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.628

7%)[5].ApreviousstudybyLofthusetal.reportedthatelevatedASTlevelsabovetheULNwerecommon(occurringin85%)inthesettingofSTEMI.OtherstudieshavereportedthattheincidenceofmarkedlyelevatedAST(>400U/L)inpatientswithSTEMIwas3–5%.TheyalsofoundthatpatientswithmarkedlyelevatedASThadahighermortalityratethanthosewithoutmarkedlyelevatedAST[11–13].Inthisstudy,wefoundthatthe30-daymortalityrateinpatientswithmarkedlyelevatedASTnotduetoliverdiseasewas14.2%,19.6%,and65.5%forskeletalmuscledamage,cardiacmuscledamage,andhematologicdisorders,respectively.Inthepresentstudy,wearbitrarilyusedacutofflevelof400U/LformarkedlyelevatedASTlevels.Previousstudiesonpatientswithmarkedlyelevatedaminotransferaselevelsduetoliverdiseaseshowedthatall-causemortalityratecorrelatedwithincreasingaminotransferaselevels.Thereportedall-causemortalityrateswere16–22%,30–45%,and31–55%inpatientswithaminotransferaselevels>400U/L[25–27],>1000U/L[27–29],and>3000U/L,respectively[30,31].OurstudyshowedthatthemagnitudeofpeakASTlevels

---

### Chunk 14/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** discussion | **Similarity:** 0.626

causemortalityrateswere16–22%,30–45%,and31–55%inpatientswithaminotransferaselevels>400U/L[25–27],>1000U/L[27–29],and>3000U/L,respectively[30,31].OurstudyshowedthatthemagnitudeofpeakASTlevelsduringthecourseofextrahepaticinjurysigniﬁcantlycorrelatedwith30-daymortality,withratesof12.8%,26.7%,and50.0%inpatientswithpeakASTlevels<1000U/L,<3000U/L,and�3000U/L,respectively.Inthemultivariateanalysis,etiology,peakASTlevels,age,albuminlevel,andcreatininelevelwereindependentfactorsassociatedwithmortality.Incontrast,factorsreﬂectingliverfunction,includinghepaticdecompensation,bilirubinlevel,ALTlevel,andPT-INR,werenotfoundtobeassociatedwithmortality.Inclinicalpractice,patientswithmarkedlyelevatedaminotransferaselevelswithnoevidenceofliverdiseasepresentasigniﬁcantchallengetophysiciansduetotheirhighmortality.Inthisstudy,among5644patientswithAST>400U/L,only7.6%werefoundtobeassociatedwithnon-hepaticcauses.ThissuggeststhatmarkedlyelevatedASTlevelsunrelatedtoliverdiseasemaynotbeencounter

---

### Chunk 15/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.626

derly subjects. Age Ageing 1987;16:94-
100.38. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, 
Del Vecchio E, et al. Updated definitions of healthy 
ranges for serum alanine aminotransferase levels. Ann 
Intern Med 2002;137:1-10.39. Häkkinen K, Alén M. Training volume, androgen use 
and serum creatine kinase activity. Br J Sports Med 
1989;23:188-9.40. Koutedakis Y, Raafat A, Sharp NC, Rosmarin MN, 
Beard MJ, Robbins SW. Serum enzyme activities in 
individuals with different levels of physical fitness. J 
Sports Med Phys Fitness 1993;33:252-7.41. Garcin-Webb P, Bhagat CS, Beilby JP. Plasma creatine 
kinase/aspartate aminotransferase ratio in the diagnosis 
of acute myocardial infarction. Clin Chem 1985;31:498-
9.42. Weibrecht K, Dayno M, Darling C, Bird SB. Liver 
aminotransferases are elevated with rhabdomyolysis in 
the absence of significant liver injury. J Med Toxicol 
2010;6:294-300.43. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N.

---

### Chunk 16/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.626

have AST/
ALT ratios >2.0 as a risk factor.110 Furthermore other acute hepatic toxicities, e.g. paracetamol, can have AST/ALT ratios 
over 2.0.111 Drug induced hepatitis is typically associated with higher serum AST compared to ALT112 particularly when the drug is known to damage mitochondria.113 Some drugs (e.g.

---

### Chunk 17/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.620

indexdatewasde-finedasthepeakASTlevel.ThreegradesfortheseverityofASTelevationwereappliedbasedonthepeakASTlevel:(1)peakASTlevels<1000U/L(as400U/L�AST<1000U/L),(2)peakASTlevels<3000U/L(as1000U/L�AST<3000U/L),and(3)peakASTlevels�3000U/L.2.3.DeﬁnitionsandClassiﬁcationsPatientswithmarkedlyelevatedASTlevelsduetohepatobiliarycauseswereexcludedfromthestudy.Hepatobiliarycausesincludedthefollowing:(1)pancreatobiliarydiseases,includingcholangitis,cholecystitis,andpancreatitis;(2)hepatocellulardiseases,includingdrug-inducedliverinjury,viralhepatitis,autoimmunehepatitis,pregnancy-relatedliverdisorder,alcoholicliverdisease,liverinvolvementinsystemicinfection,andacutehepatitisofunknownorigin;(3)liversurgeryorlivertrauma;(4)hepatobiliarymalignancy;and(5)ischemichepatitis.PatientswithmarkedlyelevatedASTlevelsduetonon-hepatobiliarycauseswereclassiﬁedintothreegroupsaccordingtoetiology:(1)skeletalmuscledamage,(2)cardiacmuscledamage,and(3)hematologicdisorder(Figure1).2.3.1.SkeletalMuscleDamageS

---

### Chunk 18/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.616

inaseaspredictorofclinicalcourseinrhabdomyolysis:A5-yearintensivecaresurvey.IntensiveCareMed.2003,29,1121–1125.[CrossRef]10.Vangstad,M.;Bjornaas,M.A.;Jacobsen,D.Rhabdomyolysis:A10-yearretrospectivestudyofpatientstreatedinamedicaldepartment.Eur.J.Emerg.Med.2019,26,199–204.[CrossRef]11.Lofthus,D.M.;Stevens,S.R.;Armstrong,P.W.;Granger,C.B.;Mahaffey,K.W.PatternofliverenzymeelevationsinacuteST-elevationmyocardialinfarction.Coron.ArteryDis.2012,23,22–30.[CrossRef][PubMed]12.Moon,J.;Kang,W.;Oh,P.C.;Seo,S.Y.;Lee,K.;Han,S.H.;Ahn,T.;Shin,E.SerumtransaminasedeterminedintheemergencyroompredictsoutcomesinpatientswithacuteST-segmentelevationmyocardialinfarctionwhoundergoprimarypercutaneouscoronaryintervention.Int.J.Cardiol.2014,177,442–447.[CrossRef][PubMed]13.Gao,M.;Cheng,Y.;Zheng,Y.;Zhang,W.;Wang,L.;Qin,L.Associationofserumtransaminaseswithshort-andlong-termoutcomesinpatientswithST-elevationmyocardialinfarctionundergoingprimarypercutaneouscoronaryintervention.BMCCardiovasc.Disord.2017,17,4

---

### Chunk 19/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.615

sofmarkedlyelevatedASTlevelsanddemonstratedthatetiologyaffectspatientsurvival.Tothebestofourknowledge,therehavebeennostudiesontheprognosisofpatientswithmarkedlyelevatedASTlevelsunrelatedtoliverdisease.Inpreviousstudies,mortalityratesinpatientswithrhabdomyolysisrangedfrom3%to46%dependingonthestudypopulation,frequencyofacutekidneyinjury,comorbidities,andcauseofrhabdomyolysis[4–10].Aprevious

J.Clin.Med.2023,12,310
10of12
studybyWeibrechtetal.reportedthatelevatedAST(>40U/L)occurredin93%ofpatientswithrhabdomyolysis[7].Raurichetal.reportedthattheincidenceofelevatedaminotransferases>1000U/LinICUpatientswithrhabdomyolysiswas24.3%.Moreover,theyfoundthatpatientswithrhabdomyolysis-relatedelevatedaminotransferaselevels(>1000U/L)hadhighermortalitythanpatientswithlowaminotransferaselevels(69.4%vs.14.7%)[5].ApreviousstudybyLofthusetal.reportedthatelevatedASTlevelsabovetheULNwerecommon(occurringin85%)inthesettingofSTEMI.OtherstudieshavereportedthattheincidenceofmarkedlyelevatedAST(>400U/L)inpatient

---

### Chunk 20/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** discussion | **Similarity:** 0.615

dingtoetiology:skeletalmuscledamage,cardiacmuscledamage,andhematologicdisorder.Binarylogisticregressionanalysiswasperformedtoevaluatethefactorsassociatedwith30-daymortality.ThemostcommonetiologyformarkedlyelevatedASTlevelswasskeletalmuscledamage(54.2%),followedbycardiacmuscledamage(39.1%)andhematologicdisorder(6.7%).The30-daymortalityratesfortheskeletalmuscledamage,cardiacmuscledamage,andhematologicdisordergroupswere14.2%,19.5%,and65.5%,respectively.ThemagnitudeofthepeakASTlevelsigniﬁcantlycorrelatedwith30-daymortality,withratesof12.8%,26.7%,and50.0%forpeakASTlevels<1000U/L,<3000U/L,and�3000U/L,respectively.Inthemultivariateanalysis,cardiacmuscledamage(oddsratio[OR]=2.76,95%conﬁdenceinterval[CI]=1.31–5.80),hematologicdisorder(OR=9.47,95%CI=2.95–30.39),peakAST<3000U/L(OR=2.94,95%CI=1.36–6.35),andpeakAST�3000U/L(OR=9.61,95%CI=3.54–26.08)wereassociatedwithincreased30-daymortality.OurstudyrevealedthreeetiologiesofmarkedlyelevatedASTunrelatedtoliverdiseaseandshowedthatetiolo

---

### Chunk 21/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.609

ydrogenase,AST,andALTwhichmaybereleasedintothecirculationfollowingmuscleinjury[21].ElevatedASTlevelsduetocardiacmuscledamagemaythusbeexplainedbythereleaseofASTfromthemyocardiumduetoincreasedstress,acuteischemiaandnecrosisinacutecoronarysyndromeandreperfusioninjury[22].Lastly,hepaticinﬁltrationbymalignanthematologicdisorders,suchasleukemia,lymphoma,andmultiplemyeloma,andnon-malignanthematologicdisorders,suchasidiopathicmyeloﬁbrosis,hemolyticanemia,polycythemiavera,myelodysplasticsyndrome,andhemophagocyticlymphohistiocytosis,mayalsocauseASTelevation[17,18,23].Addition-ally,hemolysis,irondepositionintheliver,repeatedtransfusions,concomitantinfection,anddisseminatedintravascularcoagulationmaycontributetoelevatedASTinpatientswiththisgroup[15,24].Weidentiﬁedthethreemainnon-hepaticetiologiesofmarkedlyelevatedASTlevelsanddemonstratedthatetiologyaffectspatientsurvival.Tothebestofourknowledge,therehavebeennostudiesontheprognosisofpatientswithmarkedlyelevatedASTlevelsunrelatedtoliverdisease

---

### Chunk 22/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** discussion | **Similarity:** 0.606

ase (MELD) 
scores.75,76 A raised AST/ALT ratio of only slightly above 1 (1.09) is predictive of the progression of chronic viral hepatitis 
C to cirrhosis.77It is therefore the elevation of AST, rather than ALT, which 
is predictive of fibrosis and other ratios involving AST, such 
as the AST to Platelet Ratio Index (APRI)78 and FIB4 index (which involves the four parameters: AST, ALT, platelets and 
age) are also more predictive.79,80 The reason why the AST is more elevated than ALT with progression of fibrosis is 
uncertain but may be either because of increased production, 
such as mitochondrial release,81,82 or a relatively reduced clearance.83Chronic viral hepatitis may also progress to hepatocellular 
carcinoma, however GGT is the best predictor of this 
complication, while AST is not predictive in multivariate 
analysis and ALT is not predictive at all.84 Alcoholic Hepatitis
The predominance of AST over ALT in alcohol-related liver 
disease was first reported by Harinasuta et a

---

### Chunk 23/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.603

.56. Gitlin N. The serum glutamic oxaloacetic transaminase/
serum glutamic pyruvic transaminase ratio as a 
prognostic index in severe acute viral hepatitis. Am J 
Gastroenterol 1982;77:2-4.57. Sunheimer R, Capaldo G, Kashanian F, Finck C, Woo 
J, Korins M, et al. Serum analyte pattern characteristic 
of fulminant hepatic failure. Ann Clin Lab Sci 
1994;24:101-9.58. Williams AL, Hoofnagle JH. Ratio of serum aspartate 
to alanine aminotransferase in chronic hepatitis; 
relationship to cirrhosis. Gastroenterology 1988;95:734-
9.59. Cadiot G, Ink O, Boutron A, Hanny P, Laurent-Puig P, 
Buffet C. Mitochondrial aspartate aminotransferase in 
nonalcoholic cirrhosis. Gastroenterology 1989;97:240-
1.60. Reedy DW, Loo AT, Levine RA. AST/ALT ratio > or = 
1 is not diagnostic of cirrhosis in patients with chronic 
hepatitis C. Dig Dis Sci 1998;43:2156-9.61. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT 
ratio predicts cirrhosis in patients with chronic hepatitis 
C virus infection.

---

### Chunk 24/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** methods | **Similarity:** 0.601

anbay A, Angulo P, Taniai M, Burgart 
LJ, Lindor KD, et al. Hepatocyte apoptosis and fas 
expression are prominent features of human nonalcoholic 
steatohepatitis. Gastroenterology 2003;125:437-43.6.  Wroblewski F. The significance of alterations in 
transaminase activities of serum and other body fluids. 
Adv Clin Chem 1958;1:313-51.7. Goldberg DM. Enzymes in the diagnosis of myocardial 
infarction and liver disease. Ann Clin Biochem 
1971;8:195-200.8. Goldberg DM. Clinical Enzymology. In: Ellis GP, 
West GB, editors. Progress in Medicinal Chemistry. 
Amsterdam: North Holland; 1976;13:1-158.9. Goldberg DM, Fletcher MJ, Watts C. Serum adenosine 
deaminase activity in hepatic disease: a comparative 
enzymological evaluation. Clin Chim Acta 1966;14:720-
8.10. Schmidt E, Schmidt FW. [Methods and value of 
determination of glutamic acid dehydrogenase activity 
in the serum. A contribution to the importance of 
examination of enzyme relations in the serum].

---

### Chunk 25/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** results | **Similarity:** 0.600

with and 
without hyperbilirubinemia. Dig Dis Sci 2008;53:799-
802.163. Lazo M, Selvin E, Clark JM. Brief communication: 
clinical implications of short-term variability in liver 
function test results. Ann Intern Med 2008;148:348-52.164. Schmidt E, Schmidt FW, Chemnitz G, Kubale R, 
Lobers J. The Szasz-ratio (CK/GOT) as example for the 
diagnostic significance of enzyme ratios in serum. Klin 
Wochenschr 1980;58:709-18.165. Dufour DR. Is it necessary to order aspartate 
aminotransferase with alanine aminotransferase 
in clinical practice? Author’s Reply. Clin Chem 
2001;47:1134-5.

---

### Chunk 26/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.599

le 
injury.48Acute Viral Hepatitis
While it is clearly recognised that serum levels of both serum 
ALT and AST are elevated several fold in ‘acute’ viral hepatitis 
(e.g. hepatitis A and E), De Ritis was the first to describe that 
the ALT is usually higher than the AST with the AST/ALT 
ratio usually well below 1.0, and typically in the range 0.5 to 
0.7.49-54 It is important to note that the diagnosis of acute viral hepatitis today (when serology and PCR can clearly diagnose 
a viral cause) is very different to that question 60 years ago. 
Nevertheless, even today, when transaminases are elevated 
several fold, a low De Ritis ratio still provides an important 
clue to aetiology of acute hepatitis.Investigators have however noted that acute viral hepatitis can occasionally cause a high AST/ALT ratio of up to 2.0, 
however these are atypical cases representing fulminant 
hepatitis where there is often a very poor prognosis.

---

### Chunk 27/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.598

sferase in alcoholics, 
moderate drinkers and abstainers: effect on gt reference 
intervals at population level. Alcohol Alcohol 
2005;40:511-4.93. Rosman AS, Lieber CS. Diagnostic utility of laboratory 
tests in alcoholic liver disease. Clin Chem 1994;40:1641-
51.94. Matloff DS, Selinger MJ, Kaplan MM. Hepatic 
transaminase activity in alocholic liver disease. 
Gastroenterology 1980;78:1389-92.95. Diehl AM, Potter J, Boitnott J, Van Duyn MA, 
Herlong HF, Mezey E. Relationship between pyridoxal �5′-phosphate deficiency and aminotransferase levels in 
alcoholic hepatitis. Gastroenterology 1984;86:632-6.96. Nalpas B, Vassault A, Le Guillou A, Lesgourgues B, 
Ferry N, Lacour B, et al. Serum activity of mitochondrial 
aspartate aminotransferase: a sensitive marker of 
alcoholism with or without alcoholic hepatitis. 
Hepatology 1984;4:893-6.97. Rej R. Aspartate aminotransferase activity and 
isoenzyme proportions in human liver tissues. Clin 
Chem 1978;24:1971-9.98.

---

### Chunk 28/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** other | **Similarity:** 0.597

nsferase>400U/Lexclusionofothercausesofacuteliverinjury,andinanappropriateclinicalsettingofcardiac,respiratory,andcirculatoryfailure,andsepticshock).Througharetrospectivereview,patientswithcardiacmuscledamageandmarkedlyelevatedASTwereclassiﬁedintothreecategories:(1)acutecoronarysyndrome,includingSTEMIandnon-STEMI,andunstableangina,(2)inﬂammatorydisor-dersoftheheart,includingendocarditis,myocarditis,andpericarditis,and(3)perioperativemyocardialinjury(within5dayspostoperatively).2.3.3.HematologicDisorderPatientswithanelevationofASTlevelsassociatedwithdisordersofthebloodandblood-formingorganswereclassiﬁedunderthehematologicdisordergroup.WeexcludedpatientswithelevatedASTlevelsduetoconcurrentischemichepatitisbutincludedpa-tientswithhepaticinvolvementinhematologicmalignancy.Hematologicdisorderswereclassiﬁedas(1)malignant,suchasleukemia,lymphoma,andmultiplemyeloma;and(2)non-malignant,suchasparoxysmalnocturnalhemoglobinuria,thromboticthrombocy-topenicpurpura,idiopathicmyeloﬁbrosis,my

---

### Chunk 29/30
**Article:** The De Ritis Ratio: The Test of Time (2013)
**Journal:** Clinical Biochemist Reviews
**Section:** other | **Similarity:** 0.597

ement. 
London: W.B. Saunders; 1979:381-416.47. Pertusi R, Dickerman RD, McConathy WJ. Evaluation 
of aminotransferase elevations in a bodybuilder using 
anabolic steroids: hepatitis or rhabdomyolysis? J Am 
Osteopath Assoc 2001;101:391-4.

126   Clin Biochem Rev Vol 34 November 2013
48. Veropalumbo C, Del Giudice E, Esposito G, Maddaluno S, Ruggiero L, Vajro P. Aminotransferases and muscular 
diseases: a disregarded lesson. Case reports and review 
of the literature. J Paediatr Child Health 2012;48:886-
90.49. De Ritis F, Coltorti M, Giusti G. [Transaminase activity 
of human serum in viral hepatitis; preventive note]. 
Minerva Med 1955;46:1207-9.50. De Ritis F, Coltorti M, Giusti G. [Transaminase activity 
of the blood in viral hepatitis]. Boll Soc Ital Biol Sper 
1955;31:394-6.51. De Ritis F, Coltorti M, Giusti G. [Diagnostic value 
and pathogenetic significance of transaminase activity 
changes in viral hepatitis]. Minerva Med 1956;47:167-
71.52. De Ritis F, Coltorti M, Giusti G.

---

### Chunk 30/30
**Article:** Markedly Elevated Aspartate Aminotransferase from Non-Hepatic Causes (2022)
**Journal:** Journal of Clinical Medicine
**Section:** discussion | **Similarity:** 0.596

Medicine,GyeongsangNationalUniversityChangwonHospital,Changwon51472,RepublicofKorea3InstituteofHealthSciences,GyeongsangNationalUniversity,Jinju52727,RepublicofKorea4DepartmentofInternalMedicine,GyeongsangNationalUniversityHospital,Jinju52727,RepublicofKorea*Correspondence:3939lee@naver.com†Theseauthorscontributedequallytothiswork.Abstract:Therehavebeennoreportsonmortalityinpatientswithmarkedlyelevatedaspartateaminotransferase(AST)levelsfromnon-hepaticcausestodate.ThisstudyaimedtodeterminetheetiologiesofmarkedlyelevatedASTlevels>400U/Lduetonon-hepaticcausesandtoinvestigatethefactorsassociatedwithmortalityinthesecases.Thisretrospectivestudyincluded430patientswithASTlevels>400U/LunrelatedtoliverdiseaseattwocentersbetweenJanuary2010andDecember2021.Patientswereclassiﬁedintothreegroupsaccordingtoetiology:skeletalmuscledamage,cardiacmuscledamage,andhematologicdisorder.Binarylogisticregressionanalysiswasperformedtoevaluatethefactorsassociatedwith30-daymortality.Themostcommonetiologyformar

---

